In fact, the preliminary data of the clinical trial evaluated the combination of anti‐PD‐1 and MEK inhibitor, showing early indications of the efficacy of MSS non‐hypermutated CRC patients 146. This evidence concerns the gene MAP2K7 and colorectal carcinoma.